A Phase 1/2 interventional study of OP-1250 in Hormone Receptor Positive Breast Carcinoma and HER2-negative Breast Cancer, sponsored by Olema Pharmaceuticals, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Olema Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.
This is a Phase I dose escalation and dose expansion and Phase II monotherapy open--label, first--in--human study to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), to characterize the safety and pharmacokinetic (PK) profile, and to estimate the preliminary anti-tumor activity of OP-1250 as a single agent in adult subjects with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic or locally advanced breast cancer. This study comprises 2 Phases: Phase I (Part A [Dose Escalation] and Part B [Dose Expansion]) and Phase II. Patients must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease. Patients will be evaluated for treatment emergent adverse events (AEs) during study participation, and toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 153 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Olema Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).
Drug: OP-1250
Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.
Drug: OP-1250
This portion of the study further explores the clinical activity, safety, and PK of OP-1250 monotherapy at the RP2D and will estimate preliminary anti-tumor efficacy in 3 cohorts. Cohort A will enroll subjects with measurable disease without evidence of Central Nervous System (CNS) metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases.
Drug: OP-1250
Complete Estrogen Receptor ANtagonist (CERAN)
Dose Limiting Toxicities (DLT)
Number of Participants with Dose Limiting Toxicities (DLT) during Dose Escalation Only
Time frame: Up to 28 days from start of treatment
Characterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event
Characterize the incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250 in patients that had at least one treatment emergent adverse event according to NCI-CTCAE version 5.0.
Time frame: Up to 3 years, 11 months, and 17 days.
Pharmacokinetics of OP-1250
Plasma concentrations of OP-1250 assessed steady state
Time frame: AUC (0-24) at steady state after 4 weeks of administration
Anti-tumor Activity of OP-1250 (cPR)
Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines (Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)). Overall response rate which includes confirmed Partial Response (cPR).
Time frame: Imaging studies performed every 8 weeks from date of first dose through cycle 9 then afterwards every 12 weeks until date of first documented disease progression: assessed up to 3 years, 11 months, and 17 days
| Milestone | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2COHORT C ONLY) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 6 | 27 | 6 | 6 | 29 | 48 | 5 | 7 | 7 | 7 |
| Completed | 5 | 6 | 26 | 6 | 6 | 29 | 46 | 5 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Patient remained on study treatment in an extension of the protocol | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Number of Participants with Dose Limiting Toxicities (DLT) during Dose Escalation Only
| Participants | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | TOTAL (Phase 1a) | 60 mg QD (Phase 1b) | 120 mg QD (Phase1b) | Cohort A (Phase 2) | Cohort B (Phase 2) | Cohort C (Phase 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Limiting Toxicities (DLT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Characterize the incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250 in patients that had at least one treatment emergent adverse event according to NCI-CTCAE version 5.0.
| Participants | 30 mg QD | 60 mg QD | 90 mg QD | 120 mg QD | 150 mg QD | 210 mg QD | 300 mg QD | 120 mg QD (COHORT C ONLY) |
|---|---|---|---|---|---|---|---|---|
| Characterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event | 5 | 29 | 5 | 79 | 5 | 7 | 7 | 6 |
Plasma concentrations of OP-1250 assessed steady state
| ng/mL*h | 30mg QD | 60mg QD | 90mg QD | 120mg QD | 150mg QD | 210mg QD | 300mg QD |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of OP-1250 | 1956 ± 33.0 | 4014 ± 46.2 | 7668 ± 82.4 | 9163 ± 38.1 | 12580 ± 27.3 | 22439 ± 47.2 | 25438 ± 40.2 |
Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines (Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)). Overall response rate which includes confirmed Partial Response (cPR).
| Participants | 30mg QD | 60mg QD | 90mg QD | 120mg QD | 150mg QD | 210mg QD | 300mg QD | 120 mg QD (COHORT C ONLY) |
|---|---|---|---|---|---|---|---|---|
| Anti-tumor Activity of OP-1250 (cPR) | 0 | 2 | 0 | 4 | 0 | 0 | 0 | 0 |
Collected over From date of first dose until 30 days post treatment discontinuation for any cause, assessed up to 3 years, 11 months, and 17 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg QD | 1/5 (20%) | 0/5 (0%) | 5/5 (100%) |
| 60 mg QD | 5/33 (15.2%) | 4/33 (12.1%) | 29/33 (87.9%) |
| 90 mg QD | 1/6 (16.7%) | 2/6 (33.3%) | 5/6 (83.3%) |
| 120 mg QD | 5/83 (6%) | 16/83 (19.3%) | 79/83 (95.2%) |
| 150 mg QD | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| 210 mg QD | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| 300 mg QD | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| 120 mg QD (COHORT C ONLY) | 2/7 (28.6%) | 4/7 (57.1%) | 6/7 (85.7%) |
| Event | 30 mg QD | 60 mg QD | 90 mg QD | 120 mg QD | 150 mg QD | 210 mg QD | 300 mg QD | 120 mg QD (COHORT C ONLY) |
|---|---|---|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 0/7 | 2/7 |
| BronchitisInfections and infestations | 0/5 | 0/33 | 0/6 | 0/83 | 1/5 | 0/7 | 0/7 | 0/7 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/5 | 0/33 | 0/6 | 2/83 | 1/5 | 0/7 | 1/7 | 1/7 |
| COVID-19Infections and infestations | 0/5 | 1/33 | 1/6 | 0/83 | 0/5 | 0/7 | 0/7 | 0/7 |
| Bone painMusculoskeletal and connective tissue disorders | 0/5 | 0/33 | 1/6 | 0/83 | 0/5 | 1/7 | 0/7 | 0/7 |
| BacteraemiaInfections and infestations | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 0/7 | 1/7 |
| Urinary tract infectionInfections and infestations | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 0/7 | 1/7 |
| HaematemesisInfections and infestations | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 0/7 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 0/7 | 1/7 |
| Disease progressionGeneral disorders | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 1/7 | 0/7 |
| Event | 30 mg QD | 60 mg QD | 90 mg QD | 120 mg QD | 150 mg QD | 210 mg QD | 300 mg QD | 120 mg QD (COHORT C ONLY) |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/5 | 14/33 | 2/6 | 55/83 | 4/5 | 4/7 | 6/7 | 3/7 |
| VomitingGastrointestinal disorders | 1/5 | 5/33 | 1/6 | 24/83 | 2/5 | 1/7 | 5/7 | 0/7 |
| ConstipationGastrointestinal disorders | 2/5 | 6/33 | 1/6 | 16/83 | 0/5 | 4/7 | 3/7 | 3/7 |
| FatigueGeneral disorders | 2/5 | 13/33 | 0/6 | 24/83 | 1/5 | 2/7 | 4/7 | 2/7 |
| HeadacheNervous system disorders | 1/5 | 7/33 | 1/6 | 18/83 | 1/5 | 0/7 | 4/7 | 0/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/5 | 5/33 | 1/6 | 7/83 | 1/5 | 0/7 | 3/7 | 0/7 |
| Decreased appetiteMetabolism and nutrition disorders | 1/5 | 2/33 | 1/6 | 7/83 | 1/5 | 3/7 | 3/7 | 0/7 |
| HypokalaemiaMetabolism and nutrition disorders | 0/5 | 0/33 | 0/6 | 0/83 | 0/5 | 0/7 | 1/7 | 3/7 |
| PhotopsiaEye disorders | 0/5 | 0/33 | 2/6 | 5/83 | 0/5 | 0/7 | 3/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 2/5 | 6/33 | 0/6 | 14/83 | 1/5 | 0/7 | 1/7 | 1/7 |
| Age, Categorical(Participants) | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2 COHORT C ONLY) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 18 | 6 | 4 | 17 | 33 | 1 | 3 | 4 | 7 | 99 |
| >=65 years | 2 | 3 | 9 | 0 | 2 | 12 | 15 | 4 | 4 | 3 | 0 | 54 |
| Age, Continuous(years) | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2 COHORT C ONLY) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 63 (54 to 71) | 65 (34 to 79) | 60 (30 to 81) | 57 (40 to 58) | 62.5 (40 to 67) | 61 (39 to 77) | 62 (32 to 85) | 76 (40 to 85) | 65 (57 to 77) | 64 (37 to 82) | 49 (46 to 64) | 61 (53 to 68) |
| Sex: Female, Male(Participants) | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2 COHORT C ONLY) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 27 | 6 | 6 | 29 | 48 | 5 | 6 | 7 | 7 | 152 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2 COHORT C ONLY) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 8 |
| White | 5 | 5 | 20 | 4 | 5 | 24 | 39 | 5 | 7 | 6 | 7 | 127 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 4 | 2 | 0 | 2 | 3 | 0 | 0 | 1 | 0 | 13 |
| Region of Enrollment(participants) | 30 mg QD (Phase 1a) | 60 mg QD (Phase 1a) | 60 mg (Phase 1b) | 90 mg QD (Phase 1a) | 120 mg QD (Phase 1a) | 120 mg QD (Phase 1b) | 120 mg QD (Phase 2) | 150 mg QD (Phase 1a) | 210 mg QD (Phase 1a) | 300 mg QD (Phase 1a) | 120 mg QD (Phase 2 COHORT C ONLY) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 5 | 6 | 20 | 4 | 6 | 23 | 46 | 5 | 7 | 7 | 5 | 134 |
| Australia | 0 | 0 | 7 | 2 | 0 | 6 | 2 | 0 | 0 | 0 | 2 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Jul 2024, 47 months.
Results were first posted in May 2026, 1 year 9 months after primary completion. A results delay was requested in Jul 2025.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 47 months is below that.
Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palazestrant
Olema Pharmaceuticals, Inc.